Abstract
Due to the importance of nature as a source of new drug candidates, the purpose of this article is to emphasize the marine natural products, which exhibit antitubercular activity, published between January 2000 and May 2016, with 138 quotations to 250 compounds obtained from marine resources. These metabolites are organized by chemical constitution and named as simple alkyl lipids derivatives, aromatics derivatives, peptides, alkaloids, terpenoids, steroids, macrolides, and polycyclic polyketides.
Keywords: Antitubercular, marine natural products, Mycobacterium tuberculosis, marine drugs, antimycobacterial, natural product derivatives.
Current Medicinal Chemistry
Title:Antitubercular Marine Natural Products
Volume: 25 Issue: 20
Author(s): Lishu Wang, Jungfeng Wang, Juan Liu and Yonghong Liu*
Affiliation:
- Key Laboratory of Tropical Marine Bio-resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, RNAM Center for Marine Microbiology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301,China
Keywords: Antitubercular, marine natural products, Mycobacterium tuberculosis, marine drugs, antimycobacterial, natural product derivatives.
Abstract: Due to the importance of nature as a source of new drug candidates, the purpose of this article is to emphasize the marine natural products, which exhibit antitubercular activity, published between January 2000 and May 2016, with 138 quotations to 250 compounds obtained from marine resources. These metabolites are organized by chemical constitution and named as simple alkyl lipids derivatives, aromatics derivatives, peptides, alkaloids, terpenoids, steroids, macrolides, and polycyclic polyketides.
Export Options
About this article
Cite this article as:
Wang Lishu, Wang Jungfeng, Liu Juan and Liu Yonghong*, Antitubercular Marine Natural Products, Current Medicinal Chemistry 2018; 25 (20) . https://dx.doi.org/10.2174/0929867324666170113120221
DOI https://dx.doi.org/10.2174/0929867324666170113120221 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activity of (-)-Camphene Derivatives Against <i>Mycobacterium tuberculosis</i> in Acidic pH
Medicinal Chemistry Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count
Current HIV Research Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs
Current Pharmaceutical Design High Throughput Crystallography of TB Drug Targets
Infectious Disorders - Drug Targets Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment
Current Cancer Drug Targets Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Subject Index To Volume 7
Current Drug Targets Snake Venom Proteins and Peptides as Novel Antibiotics Against Microbial Infections
Current Proteomics Vitamin D Deficiency in Tuberculosis and Diabetes Mellitus - A Cluster Analysis
Current Respiratory Medicine Reviews Cognitive Performance and Neuro-Metabolites in HIV Using 3T Magnetic Resonance Spectroscopy: A Cross-Sectional Study from India
Current HIV Research Nanotechnology-Based Approaches for Combating Tuberculosis: A Review
Current Nanomaterials The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Cytokines in Candidiasis and Aspergillosis
Current Pharmaceutical Biotechnology Microsphere Technology for Chemotherapy of Mycobacterial Infections
Current Pharmaceutical Design Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder)
Current Drug Discovery Technologies Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Determination of Molecular Properties Effectuating the Growth Inhibition of Mycobacterium Tuberculosis by Various Small Molecule Hydrazides
Letters in Drug Design & Discovery